ARO Annual Meeting (February 2014)
“Impact of Kv3 Channel Modulator AUT3 on Auditory Temporal Resolution in Rats” (Rybal ko et al.).
Publications
Tweets
Autifony Therapeutics regains rights to clinical stage Kv3 programme
https://t.co/rBHjjR7aC0
RT @singular_talent:Barbara Domayne-Hayman joined us on Careers in Discovery to talk startups, careers and more.
Barbara's experience… https://t.co/u0VXnvXlGI
Autifony announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing… https://t.co/oeGgN4ooWG
Comments are closed.